Background
==========

Innate immune responses may augment adaptive immune responses via the adjuvant effect of endogenous apoptotic cell death derived nucleic acids that activate Toll-like receptors (TLRs). In animal models of lupus, activation of TLR-9 accelerates renal disease. We studied the expression of TLR-2, TLR-3, TLR-4 and TLR-9 in the peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE).

Materials and methods
=====================

Peripheral blood mononuclear cells from 18 SLE patients, four patients with other rheumatic disorders and three normal controls were studied for the expression of TLRs by FACS analysis. TLR-2, TLR-3, TLR-4 and TLR-9 expressions was studied in total lymphocytes, CD19^+^and CD14^+^cells. Disease activity was assessed by the SLEDAI. Patients were divided into those with active/severe disease and those with inactive/mild disease.

Results
=======

Eight out of 18 patients had active disease with mean SLEDAI score 12.3 (± 9.9) while 10 had inactive disease with mean SLEDAI score 2.8 (± 0.9). Lymphocyte expression of TLR-9 (mean value and standard deviation) was higher among patients with active/severe disease in comparison with patients with inactive lupus (64 ± 18%, *n*= 8 versus 19 ± 14%, *P*\< 0.003) (Table [1](#T1){ref-type="table"}).

                          Active disease (*n*= 8) (%)   Inactive disease (*n*= 10) (%)   Other rheumatic diseases (*n*= 4) (%)   Healthy controls (*n*= 3) (%)
  ----------------------- ----------------------------- -------------------------------- --------------------------------------- -------------------------------
  TLR-9 in lymphocytes    64 ± 18                       19 ± 14                          22 ± 21                                 28 ± 3
  TLR-9 in CD19^+^cells   42 ± 20                       25 ± 24                          17 ± 14                                 33 ± 5
  TLR-9 in CD14^+^cells   31 ± 18                       16 ± 13                          6 ± 5                                   24 ± 13

There were no differences between patients and healthy controls regarding the expression of TLR-2, TLR-3 and TLR-4. The expression of TLR-9 on various B-cell subpopulations of patients with SLE is currently under investigation.

Conclusions
===========

TLR-9, but not TLR-2, TLR-3 and TLR-4, is upregulated in peripheral lymphocytes from SLE patients with active/severe disease compared with patients with inactive/mild disease. There is also a trend for increased expression of TLR-9 at least on CD19^+^and CD14^+^cells. Experiments in progress examine the response of these cells to TLR stimulation.
